Filing for hundreds of additional patents for drugs already approved by the FDA in order to fend off market entry by generics and biosimilars is the key strategy among many drugmakers for keeping their drug prices high, the Initiative for Medicines, Access & Knowledge (I-MAK) says in its new report.
Source: Drug Industry Daily